Pacira BioSciences Inc (NASDAQ: PCRX)’s stock price has plunge by 2.32relation to previous closing price of 15.53. Nevertheless, the company has seen a 10.89% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-03 that — New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement — TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL® (bupivacaine liposome injectable suspension). The new J-code for EXPAREL, J0666, becomes effective January 1, 2025, and will supersede the current C-code (C9290), which has been in place since 2019.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
The price-to-earnings ratio for Pacira BioSciences Inc (NASDAQ: PCRX) is 12.35x, which is above its average ratio. Moreover, the 36-month beta value for PCRX is 0.83. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PCRX is 44.57M and currently, short sellers hold a 12.89% of that float. On October 04, 2024, PCRX’s average trading volume was 1.30M shares.
PCRX’s Market Performance
PCRX stock saw an increase of 10.89% in the past week, with a monthly gain of 4.95% and a quarterly increase of -24.55%. The volatility ratio for the week is 4.96%, and the volatility levels for the last 30 days are 5.57% for Pacira BioSciences Inc (PCRX). The simple moving average for the past 20 days is 12.39% for PCRX’s stock, with a -37.92% simple moving average for the past 200 days.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with Truist repeating the rating for PCRX by listing it as a “Sell.” The predicted price for PCRX in the upcoming period, according to Truist is $8 based on the research report published on August 13, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $14, previously predicting the price at $37. The rating they have provided for PCRX stocks is “Sector Perform” according to the report published on August 12th, 2024.
PCRX Trading at 1.57% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.80% of loss for the given period.
Volatility was left at 5.57%, however, over the last 30 days, the volatility rate increased by 4.96%, as shares surge +8.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.57% lower at present.
During the last 5 trading sessions, PCRX rose by +10.89%, which changed the moving average for the period of 200-days by -49.22% in comparison to the 20-day moving average, which settled at $14.20. In addition, Pacira BioSciences Inc saw -52.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from GAUGLER DARYL, who sale 500 shares at the price of $12.86 back on Sep 13 ’24. After this action, GAUGLER DARYL now owns 115,700 shares of Pacira BioSciences Inc, valued at $6,430 using the latest closing price.
GAUGLER DARYL, the Officer of Pacira BioSciences Inc, proposed sale 500 shares at $12.86 during a trade that took place back on Sep 13 ’24, which means that GAUGLER DARYL is holding shares at $6,430 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.68 for the gross margin
The net margin for Pacira BioSciences Inc stands at 0.09. The total capital return value is set at 0.06. Equity return is now at value 7.54, with 3.99 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is 7.34.
Currently, EBITDA for the company is 162.9 million with net debt to EBITDA at 2.31. When we switch over and look at the enterprise to sales, we see a ratio of 1.64. The receivables turnover for the company is 6.58for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.82.
Conclusion
To wrap up, the performance of Pacira BioSciences Inc (PCRX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
